Coretag Therapeutics

Based on its proprietary necrosis targeting platform technology, Coretag Holding develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis.

To fund the next steps of the pipeline development Coretag, Inc. is listing at the Nasdaq stock exchange and issues new shares to accommodate a private placement.